Biogen Idec (NASDAQ:BIIB)

biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
biotech word cloud

Short Sellers Back Off of Major Biotechs

The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Why Citi Sees Huge Upside in 4 Top Biotechs Now

If there was one sector inside of a broader health care theme that performed well through much of 2015, it was biotech. That was then, and this is now. A ...
Read Full Story »
graph

Short Interest Rises Across the Board in Major Biotechs

The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Major Biotech Short Interest Continues to Be Mixed

The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
ThinkstockPhotos-481735362

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

When some investors think about biotech, the first thoughts are of incredibly volatile companies, with clinical data and binary outcomes that can make the stocks swing up and down wildly. ...
Read Full Story »
Test tubes

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

In an almost incredible turn of events due to the massive selling among the biotechs, the four largest companies in the industry on a price-to-earnings multiple basis are actually cheaper ...
Read Full Story »
biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
automatic inspection machine

How Biogen Won at Earnings in Q4

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter financial results before the markets opened on Wednesday. The biotech giant posted $4.50 in earnings per share (EPS) on $2.84 billion in revenue. That ...
Read Full Story »
Test tubes

What to Expect From Biogen Earnings

Biogen Inc. (NASDAQ: BIIB) is set to report its fourth-quarter financial results before the markets open Wednesday. The consensus estimates from Thomson Reuters call for $4.08 in earnings per share ...
Read Full Story »
graph

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

Like all sectors in the S&P 500, biotech has struggled mightily out of the gate this year. In fact, the iShares Biotechnology ETF is down a staggering 13% since the ...
Read Full Story »
Test tubes

Short Interest Remains Mixed for Major Biotechs

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

Stocks were pounded lower yet again on Wednesday, but this time on fears of a North Korean hydrogen bomb test. The stock market is off to a rocky start in ...
Read Full Story »